The effectiveness and safety evaluation of anti-VEGF drugs on the treatment of corneal neovascularization

• Published in: Chung-hua yen k'o tsa chih Vol. 51; no. 10; p. 730
• Main Authors: Wu, Xinyi, Yang, Fuman
• Format: Journal Article
• Language: Chinese
• Published: China 01.10.2015
• Subjects: Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized; Bevacizumab - adverse effects; Bevacizumab - therapeutic use; Corneal Neovascularization - drug therapy; Humans; Ranibizumab - adverse effects; Ranibizumab - therapeutic use; Vascular Endothelial Growth Factor A - antagonists & inhibitors
• ISSN: 0412-4081
• DOI: 10.3760/cma.j.issn.0412-4081.2015.10.004

The studies and clinical applications of Ranibizumab and Bevacizumab which are new anti-VEGF drugs have made significant progression on the treatment of corneal neovascularization. The effectiveness and safety of Ranibizumab compared with Bevacizumab has been the focus of the debate for scholars nowadays. Some experiments showed that the effect of Bevacizumab was better than Ranibizumab. But combined with our experiments, Ranibizumab represented the advantages of shorter effect time, stronger affinity with VEGF-A, better tolerance with repeated injections etc. So we believed that the adequate doses of ranibizumab had better effects. Its clinical application should be paid much attention.